Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Experimental group 1:the oral trial drug favipiravir tablets plus chloroquine phosphatetablets tablets group
Experimental group 2:the oral trial drug favipiravir tablets
Control group:the oral placebo treatment
Sponsors
Beijing Chao-yang Hospital, Capital Medical University
Eligibility
Sex/Gender
Male
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Male and female aged 18-75 years old; 2. Patients previously diagnosed with COVID-2019: the course of illness is no more than 14 days;If the course of disease was more than 14 days, patients meeting one of the following conditions could also be included: (1) no obvious absorption or progression of chest lesions within 7 days; (2) respiratory symptoms (chest tightness, or cough, or breathing difficulties); Nucleic acid positive within 3 days 3. sign the informed consent; 4. Agree to collect clinical samples; 5. Female or male subjects of childbearing age agree to take effective contraceptive measures within 3 months of the last oral medication to ensure that female or male partners of childbearing age are not pregnant.
Exclusion criteria
Exclusion criteria: 1. Cases of severe vomiting or difficulty in ingesting medication; 2. Pregnant and lactating women; 3. Lopinavir/ridonavir, ribavirin, interferon and monoclonal antibody were received 3 days before enrollment; 4. Cases of respiratory failure requiring mechanical ventilation; 5. Cases of shock; 6. Complications of other organ failure require ICU care; 7. Patients were clinically predicted with no hope of survival and only received hospice care, or those who were in a deep coma and did not respond to supportive treatment measures within three hours of admission.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| improvement or recovery of respiratory symptoms;viral nucleic acid shedding; | — |
Countries
China
Contacts
Public ContactZhaohui Tong
Beijing Chao-yang Hospital, Capital Medical University
Outcome results
None listed